Class II โ€” Potential Health Hazard

Potential health hazard โ€” use of or exposure to this product may cause temporary or medically reversible adverse health consequences.

ranitidine hydrochloride Recalled by PD-Rx Pharmaceuticals, Inc. Due to CGMP Deviations: Received notice from supplier of potential...

Date: January 10, 2020
Company: PD-Rx Pharmaceuticals, Inc.
Status: Terminated
Source: FDA (Drug)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact PD-Rx Pharmaceuticals, Inc. directly.

Affected Products

ranitidine hydrochloride, USP ,150 mg tablets a) 14-count bottles ( NDC 43063-844-14); b) 30-count bottles (NDC 43063-844-30); c) 60 -count bottles( NDC 43063-844-60); d) 90-count bottles (NDC 43063-844-90); e) 100-count bottles ( NDC 43063-844-01), Rx Only, Distributed by: PD-Rx Pharmaceuticals Incorporated Oklahoma City, OK 73127

Quantity: N/A

Why Was This Recalled?

CGMP Deviations: Received notice from supplier of potential -Nitrosodimethylamine (NDMA) amounts above established levels.

Where Was This Sold?

This product was distributed to 12 states: AZ, CA, FL, IL, IN, KY, ME, MS, OK, OR, PA, TN

Affected (12 states)Not affected

About PD-Rx Pharmaceuticals, Inc.

PD-Rx Pharmaceuticals, Inc. has 25 total recalls tracked by RecallDetector.

Related Recalls

Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report